This report delivers an in-depth understanding of the CAR T-Cell Therapy use for Multiple Myeloma as well as the CAR T-Cell Therapy market trends for Multiple Myeloma in the 6MM i.e., United States and EU5 (Germany, Spain, Italy, France and the United Kingdom).
The Multiple Myeloma CAR T-Cell Therapy market report provides current treatment practices, emerging drugs, CAR T-Cell Therapy market share of the various CAR T-Cell Therapies for Multiple Myeloma, the individual therapies, current and forecasted Multiple Myeloma CAR T-Cell Therapy market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Multiple Myeloma treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses underlying potential of the market.
Reasons to Buy
The report will help in developing business strategies by understanding trends shaping and driving the Multiple Myeloma CAR T-Cell Therapy market
To understand the future market competition in the Multiple Myeloma CAR T-Cell Therapy market and Insightful review of the key market drivers and barriers
Organize sales and marketing efforts by identifying the best opportunities for CAR T-Cell Therapy for Multiple Myeloma in US and Europe (Germany, Spain, Italy, France and United Kingdom).
Identification of strong upcoming players in market will help in devising strategies that will help in getting ahead of competitors
Organize sales and marketing efforts by identifying the best opportunities for Multiple Myeloma CAR T-Cell Therapy market
To understand the future market competition in the Multiple Myeloma CAR T-Cell Therapy market
Report Highlights
In the coming years, Multiple Myeloma CAR T-Cell Therapy market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the Size of the market to enable the drug manufacturers to penetrate more into the market
The companies and academics are working to assess challenges and seek opportunities that could influence CAR T-Cell Therapy R&D activities for Multiple Myeloma. The therapies under development are focused on novel approaches to treat/improve the disease condition
Major players are involved in developing CAR T-Cell Therapy for Multiple Myeloma. Launch of emerging therapies, will significantly impact the Multiple Myeloma CAR T-Cell Therapy market
A better understanding of disease pathogenesis will also contribute to the development of novel CAR T-Cell Therapies for Multiple Myeloma
The in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities
Key Topics Covered:
1. Key Insights
2. Executive Summary
3. CAR T-Cell Therapy Market Overview at a Glance
3.1 Market Share (%) Distribution of CAR T-Cell Therapy for MM in 2030
4. CAR T-Cell Therapy Background and Overview
4.1 Introduction
4.1.1 CARs Generations
4.1.2 Genetic Engineering of T-Cells
4.1.3 How CAR T-Cell Therapy Works
4.2 The promise of CAR T-cell targeting B cell maturation antigen (BCMA) in multiple myeloma
4.3 Current challenges in CAR T
4.3.1 Therapeutic side effects
4.3.2 CAR T-cells lack of success
4.4 CAR T-cell therapy: Route to reimbursement
4.5 Unmet needs
5. CAR T-Cell Therapy for Multiple Myeloma (MM): 6 Major Market Analysis
5.1 Key Findings
5.2 Market Size of CAR T-Cell Therapy in 6MM
5.2.1 Market Size of CAR T-Cell Therapy by Therapies
6. Market Outlook
7. Emerging Drug Profiles for Multiple Myeloma
7.1 bb2121: Celgene Corporation
7.1.1 Product Description
7.1.2 Research and Development
7.1.3 Product Development Activities
7.2 JNJ-68284528 (LCAR-B38M): Janssen Research & Development
Fitness International, LLC opened a new Club Studio location in Kingwood, Texas. The new 40,000 square foot club features five innovative boutique fitness studios that were carefully curated to create a unique experience, along with recovery services...
Mirum Pharmaceuticals, Inc. today announced that on May 10, 2024, the Compensation Committee of Mirum's Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 38,600 shares of common stock and 19,300...
Evolus, Inc. , a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant of non-qualified stock options to purchase an aggregate of 10,990 shares of Evolus and an aggregate of 42,759...
Inhibrx, Inc. ("Inhibrx," or the "Company") today announced that in connection with the previously announced distribution by the Company of 92% of shares of common stock of its subsidiary Inhibrx Biosciences, Inc. ("SpinCo") to holders of shares of...
Asia Green Biotechnology Corp. ("Asia Green" or the "Company") announces that, further to its news releases dated April 17, 2024, April 26, 2024, and May 8, 2024, the Management Cease Trade Order ("MCTO") issued by the...
The following statement is being issued by Rice Harbut Elliott LLP regarding the Ruckman v. Biotrade Canada Ltd. et al. lawsuit:
All persons in Canada who purchased or ingested U-Dream on or after August 18, 2014 (the "Class" or "Class Members")...